Please login to the form below

Not currently logged in
Email:
Password:

Japanese pharmacos aid earthquake efforts

Several Japanese pharma companies have offered donations of both money and medical supplies to help with aid efforts following the Tohoku earthquake

Several Japanese pharma companies have offered donations of both money and medical supplies to help with aid efforts following the Tohoku earthquake.

The earthquake, which triggered tsunamis across Japan's eastern coastline, has killed at least 1,600 people, with thousands missing and many more left without homes.

Takeda Pharmaceutical has said it will donate 300m Japanese Yen (about £2.3m) to the Japanese Red Cross Society to help the emergency relief fund. Donations of pharmaceutical products have also been offered by the Osaka-based company.

Daiichi Sankyo also announced it would make a donation to the Japanese Red Cross worth 100m Japanese Yen (about £760,000), as well as implementing a programme to match donations made by its employees. The company also said it is looking to donate medical supplies to affected areas.

Other companies to offer donations to the Japanese Red Cross include Astellas (100m Japanese Yen); Chugai Pharmaceutical (100m Japanese Yen); and Eisai (200m Japanese Yen – about £1.5m).

Eisai also said it is to establish a crisis centre in the Tohoku region to help implement ongoing support in the affected areas.

To donate to the fund, visit the Red Cross Japan Tsunami Appeal.

14th March 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics